Saxenda® (liraglutide) and nausea

Nausea in the US, EU and Canadian documents

Saxenda® is liraglutide 3 mg, injected once a day for weight management. Its three main sets of product information use different counting rules, but they agree that nausea comes first. ^[1][2][3] The US and Canadian tables draw on the same five placebo-controlled adult trials, which ran for 32 to 56 weeks, so their percentages match; the US label adds a separate 56-week trial in adolescents. ^[1][3]

What 39 in 100 actually means

These figures count anyone who mentioned nausea at least once during months of treatment. They are not the share of people who feel queasy on a given day. About one in seven people on placebo also reported it, because diet changes, infections and everyday life cause nausea too. ^[1]

Stomach and bowel complaints as a group affected 67.9% of adults on Saxenda® against 39.3% on placebo. Severe ones were reported by 4.8% against 1.4%, and 6.2% against 0.8% stopped treatment because of them. ^[3] Nausea alone led 2.9% of adults to stop, compared with 0.2% on placebo. ^[1]

Two groups may be more affected. The EU and Canadian documents say people aged 65 or older may experience more digestive effects, and the EU summary adds people with mild or moderate kidney impairment. ^[2][3]

What the liraglutide 3 mg trials add

In SCALE Obesity and Prediabetes, the largest trial, with 3,731 adults without diabetes, the most frequent adverse events on liraglutide were nausea and diarrhea, mostly mild or moderate. ^[4]

An earlier 20-week European trial looked at nausea more closely. Among 93 people on 3 mg, 48% reported some nausea and 13% some vomiting, most episodes fell in the first six weeks while the dose was rising, and four people withdrew. ^[5] Those who felt sick lost an average of 9.2 kg over a year against 6.3 kg for those who did not, yet both did better than placebo, and quality-of-life scores improved similarly. ^[5] Nausea is therefore not a requirement for the medicine to work.

In the adolescent trial published in 2020, digestive side effects affected 64.8% of teens on liraglutide and 36.5% on placebo, and 10.4% stopped treatment because of side effects, against none on placebo. ^[6]

Why liraglutide can unsettle the stomach

What the label establishes: liraglutide delays gastric emptying, and GLP-1 receptors sit in brain areas that control appetite, where liraglutide was found in animal studies. ^[1] The label lists nausea as a reaction but does not say which of these effects produces it.

What studies have measured: in a randomised Mayo Clinic trial of 40 adults, liraglutide 3 mg slowed the emptying of a solid meal by a median 70 minutes at week 5, but only about 30 minutes at week 16, and 12 of 19 people on liraglutide had nausea against 4 of 21 on placebo. ^[7] A separate study found that stomach emptying in the first hour after a meal was 23% slower than placebo after five weeks on 3 mg. ^[8] A smaller delay later in treatment fits the label’s observation that nausea becomes less common over time, although neither study proved that link for individuals.

What is general knowledge: MedlinePlus lists slow stomach emptying and medicines among common causes of nausea. ^[9] Liraglutide peaks in the blood about 11 hours after an injection and has a half-life of around 13 hours. ^[1] Whether the timing of your injection shapes when nausea appears has not been studied, and the label lets you inject at any time of day.

When the queasiness may come from something else

• Everyday causes MedlinePlus lists: stomach infections, food poisoning, reflux, migraine, motion sickness, pregnancy and severe pain such as kidney stones. ^[9]
• Pregnancy matters twice here: morning sickness can look like a side effect, and the US label says Saxenda® should be stopped once pregnancy is recognised. ^[1]
• Pancreatitis and gallbladder problems are listed Saxenda® warnings, and both can bring nausea together with persistent upper belly pain. ^[1]
• Low blood sugar, possible if you also take insulin or a sulfonylurea or are a teenager on Saxenda®, can include feeling sick among its warning signs in the Canadian and EU leaflets. ^[2][3]
• More serious conditions such as appendicitis, a blocked bowel or an ulcer can start with nausea and vomiting. ^[9]

Steps the sources describe

The label builds the start of Saxenda® around stomach tolerance: 0.6 mg a day for a week, then a weekly rise to 3 mg from week five. Adults who struggle with a step may have it delayed by about a week, and teenagers may drop back to the previous dose, with escalation taking up to eight weeks. After more than three days without a dose, the climb starts again at 0.6 mg. ^[1] Any change to your schedule is your prescriber’s call.

Fluids come first in the patient leaflets: the Medication Guide asks you to drink fluids to lower the chance of dehydration, and the EU leaflet, noting that fluid loss is most likely early in treatment, stresses drinking plenty to avoid it. ^[1][2]

MedlinePlus self-care advice for nausea includes sitting quietly when it comes on, eating several small meals instead of three large ones, choosing bland or watery foods, sitting up rather than lying down after eating, getting fresh air, and avoiding greasy, very salty, spicy or strongly smelling foods as well as caffeine, alcohol and fizzy drinks. ^[10] It notes that anti-nausea medicines exist; ask a pharmacist or your prescriber before using one alongside Saxenda®. ^[10] Saxenda® itself can be taken with or without food. ^[1]

Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help